The partnership will support the development of novel technologies in drug discovery, accelerate scientific talents across Canada, and advance Canada’s position as an international leader for healthcare innovation.
The partnership will significantly enrich GlycoNet’s and API’s capacities to support companies with innovations in glycomics.
GlycoNet researchers at Simon Fraser University are developing new molecules with the ultimate goal to improve the effectiveness of antitumor antibodies.
GlycoNet scientists solved the structure of an enzyme that could help burn victims and prevent deaths from different kinds of infections.
The direct biochemical approach helps direct cells to specific sites for more efficient and targeted treatment.
Canadian Glycomics Network
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
© CANADIAN GLYCOMICS NETWORK (GLYCONET). ALL RIGHTS RESERVED.